Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > RepliCel applies to TSX-V to extend warrants

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon May 10, 2023 7:52pm

82 Views

Post# 35442064

RE:RE: RE:RepliCel applies to TSX-V to extend warrants

Well the good news is, the roulette ball won't drop on red. Even as a 25%er, there will be a payday... it unfortunately could be much less than what it should be.

I hate to assume the worst here.. so I am staying optimistic that their intentions are not to screw us loyal shareholders.

I would be thrilled if there was a $5/share buyout... but similarly disappointed because in my gut I believe the sky is the limit and far exceeds this

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario